How interleukin‐1β induces gouty arthritis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Recent clinical trials with IL-1β blockade have revealed an impressive and sustained reduction in recurrent attacks of gouty arthritis (1).Even with the use of allopurinol to reduce the systemic levels of uric acid and the anti-inflammatory properties of colchicine, there is no dearth of patients with recurrent episodes of painful gouty arthritis poorly controlled with these regimens who require intermittent courses of glucocorticoids.Thus, the success of IL-1β blocking therapies is a welcome addition for treating refractory gouty arthritis in these patients.Despite the availability of several widely used TNFα blocking therapies for rheumatoid arthritis and other autoimmune diseases, there is a paucity of reports that blocking TNFα provides an effective reduction in gout severity.One explanation for the lack of clinical trials of TNFα blockade in gout attacks is reluctance of subjecting these patients to suppression of host-defense by TNFα blockers.An alternative explanation is that efficacy of TNFα blockade in refractory gout is less than expected.One study reports a weak response with rather high doses of infliximab (2).There are also few publications on monosodium urate (MSU) crystals inducing TNFα from human and mouse cells unless co-stimulated with endotoxins.Therefore, IL-1β blockade may be used for inducing long-term remissions in refractory patients and replace glucocorticoids.If IL-1β blockade becomes the standard of care in refractory gout, it would be consistent with the unique role of IL-1β in the pathogenesis of auto-inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nguyen, M. T. A., Favelyukis, S., Nguyen, A.-K., Reichart, D., Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G., & Olefsky, J. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706762200 · Cited by 1,035
Cited by
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationTargeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Self-citationMayer-Barber, K. D., Andrade, B. B., Barber, D. L., Hieny, S., Feng, C. G., Caspar, P., Oland, S., Gordon, S., & Sher, A. (2011) · Immunity · doi:10.1016/j.immuni.2011.12.002 · Cited by 418
Klück, V., Jansen, T. L. T. A., Janssen, M., Comarniceanu, A., Efdé, M., Tengesdal, I. W., Schraa, K., Cleophas, M. C. P., Scribner, C. L., Skouras, D. B., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30065-5 · Cited by 311
Self-citation
Metadata
- Authors
- Dinarello, C. A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-10-29
- Volume
- 62
- Issue
- 11
- Pages
- 3140-3144
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2023269368
- Cited by
- 58
- References
- 1
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How interleukin‐1β induces gouty arthritis. https://app.cochat.ai/papers/10.1002/art.27663
- The paper
- Dinarello, C. A. (2010). How interleukin‐1β induces gouty arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.27663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.